What are the opening hours?

Monday 8am - 5pm Tuesday 8am - 5pm Wednesday 8am - 5pm Thursday 8am - 5pm Friday 8am - 5pm

UF Center for Musculoskeletal Pain Research

Home
United States
Gainesville, FL
UF Center for Musculoskeletal Pain Research

The Center for Chronic Pain & Fatigue Research focuses on the study of musculoskeletal pain/fatigue

02/16/2026

If you are 18-80 years old and experience temporomandibular (TMJ) pain along with another chronic pain condition (such as low back pain, fibromyalgia, or headaches), you may be eligible to participate in a research study designed to examine the potential benefits of journaling in alleviating pain. Compensation provided. If you are interested, call, or email a member of the study team: 352-273-9029; TMDStudy@dental.ufl.edu

02/07/2026

Researchers recently compared the cost-effectiveness of pregabalin (Lyrica), duloxetine (Cymbalta), milnacipran (Savella) and amitriptyline (Elavil) in the treatment of fibromyalgia using a simulated study population based on published data. They found that duloxetine 120 mg offered the best mix of health benefits and cost savings. It outperformed the older, cheaper option amitriptyline and gave more quality‑adjusted life‑years for a slightly higher cost. Pregabalin 450 mg actually came in second, though its effect was slightly smaller than duloxetine’s at a higher cost. The remaining choices, milnacipran and lower‑doses of pregabalin or duloxetine were either less effective or more expensive. When societal costs were considered, the duloxetine and pregabalin were actually considered cost saving. While it’s important to remember that not every person responds to medications the same way, this could help you decide which drug offers the best return on health for the money spent. It also should encourage insurers to support access to these medications from a societal perspective of reducing disease burden.

01/24/2026

The 2026 US Dietary Guidelines brought back the food pyramid in a new way. The food pyramid was inverted to prioritize protein, dairy, healthy fats, fruits, and vegetables at the top while moving whole grains to the smaller base. The new guidelines emphasize cutting back on highly processed foods and reducing added sugars, which are both strongly supported by current scientific evidence. The higher protein recommendations of 1.2-1.6g/kg of body weight also aligns with recent recommendations (and fortunately, the majority of Americans already meet this goal). The saturated fat recommendations are a bit confusing—the 2026 guidelines do still recommend that saturated fat should not exceed 10% of your total daily calories, but they emphasize the importance of full-fat dairy products and animal-based proteins and fats, both of which are high in saturated fats. Multiple studies show that replacing saturated fats like butter with soybean or canola oil can actually improve your heart health. Whole grains, legumes and beans are also cost-effective, important dietary staples that can help you meet your daily fiber goals! As you can see, the new recommendations are somewhat controversial and will need further discussion.

12/22/2025

The holidays are often full of delicious food, which can sometimes seem daunting when you are trying to eat healthier. We all know that eating well is important to help manage pain and your overall health. Eating well doesn’t mean being perfect—and one meal or one day won’t make or break your health. Small choices add up over time. Over the holidays, you can and should still enjoy your favorite foods mindfully! Try to include a protein, fruits/veggies and whole grains with each of your meals to maintain a bit of balance. Don’t forget to stay hydrated as well!

12/19/2025

Movement can help reduce pain and stiffness in fibromyalgia—but it doesn’t have to look like a workout. Studies show that gentle, regular activity is often most helpful. It can often be a bit harder to stay active over the holidays, so it’s important to find movement that works for you and your schedule. Try taking breaks and stretching during a movie marathon, playing with kids/pets, or taking a walk around the neighborhood or a local park to see the Christmas lights! Any movement counts and you can break your activities up into shorter bursts throughout the day to better fit your schedule and energy levels.

12/14/2025

Tramadol use has increased in recent years and is perceived to be safer than other short-acting opioids. Researchers in Denmark recently conducted a systematic review of the efficacy and safety of tramadol use for chronic pain. They used data from 19 randomized, placebo-controlled trials and 6506 participants. They found low evidence that tramadol has a slight improvement of pain levels. They also found moderate evidence that it increases the risk of serious adverse events, including heart problems and tumors and low evidence of increases in non-serious adverse events, including nausea, dizziness, constipation and drowsiness. While tramadol may have a slight benefit for pain, it’s important to weigh the risk of adverse events when deciding to use it.

09/27/2025

What predictors do we have for who will go on to develop infection-associated chronic conditions (IACCs)? Female s*x is consistently linked to IACCs, which some scientists believe may provide clues to the mechanisms behind their development. Women are more susceptible to many immune-mediated conditions. Severity of the initial infection is also related to a higher risk of developing infection-associated chronic conditions, but they have also been reported in individuals who had mild or asymptomatic infections. A prospective, longitudinal study of college students identified 238 students who developed infectious mononucleosis. Of those students, 48 met the criteria for CFS 6 months after the initial infection and 18 students met more than two criteria for CFS. Compared to a control group of 58 students who had recovered from the infection, the 18 students who met two criteria for CFS had higher reports of stomach pain, bloating, and irritable bowel syndrome at baseline. They also had lower levels of the immune markers IL-13/IL-5.

09/25/2025

Long COVID offers a unique opportunity as an infection-associated chronic conditions (IACCs) as these conditions are typically identified long after the acute phase of the illness, past the point where you are able to identify the illness itself. In the context of the pandemic, many more individuals were testing and documenting their illness and there were fewer other illnesses (common cold, influenza, rhinovirus) spreading around that time. Many scientists believe Long COVID and CFS likely share root causes, like immune dysfunction, lingering viruses or viral remnants, reactivation of latent viruses, and disruption of the microbiome. If scientists can find biomarkers and effective treatments for long COVID, these discoveries may lead to similar breakthroughs for CFS, which has been underfunded and overlooked for decades.

09/23/2025

Not all infections end when the fever breaks. Some people never fully recover from viral or bacterial infections. Several names have been used to describe this phenomenon, including infection-associated chronic conditions (IACCs) and post-acute infection syndromes (PAIS). Many infections have been found to trigger long-lasting symptoms, including Epstein-Barr, influenza, polio, Ebola and most recently in the news, COVID. These long-lasting symptoms are very similar to chronic fatigue syndrome (CFS), with a range of symptoms—including post-exertional malaise, fatigue, brain fog, pain and poor sleep. Long COVID has brought more attention to this problem, as a high proportion of individuals with long COVID meet CFS criteria and the NIH launched their RECOVER initiative to better understand, prevent and treat long COVID.

09/17/2025

Tonmya (cyclobenzaprine hydrochloride) was recently approved by the FDA as a treatment for fibromyalgia. This is the first new treatment approved in 15 years, joining pregabalin (Lyrica), duloxetine (Cymbalta), and milnacipran HCl (Savella). You may recognize cyclobenzaprine as has been previously approved as an oral form as a muscle relaxant. Tonmya is a sublingual tablet designed to dissolve under the tongue and allow for rapid absorption. It is meant to be used before bedtime and significantly reduced daily pain scores when compared to placebo in two phase 3 trials. A third phase 3 trial found a reduction in pain scores, but they were not statistically significant. Among all 3 trials, the drug was well tolerated with mild side effects including oral numbness, discomfort or pain, dry mouth, canker sores, fatigue and drowsiness. It’s expected to become available next month.

09/11/2025

As we shared in our last post, autoantibodies are antibodies that attack your body’s own tissues and they have been found in a subset of fibromyalgia patients (FMS). The current study looked for some of these same autoantibodies in individuals with long-COVID, who suffer from many symptoms similar to FMS. The investigators evaluated 18 patients who reported significant pain and fatigue at least 4 weeks after recovering from COVID and 18 patients who had recovered completely. Similar to FMS Patients, they found autoantibodies to glial cells in both the FMS and both the long-COVID patients and recovered patients. After isolating these antibodies, they injected them into mice. The antibodies from the FMS patients were associated with more pain sensitivity and weaker muscles, but the antibodies from the post COVID patients did not significantly change pain sensitivity, muscle strength or the working memory of the mice. This fact suggests a different pain mechanism, maybe because long-COVID patients often have more localized pain complaints than FM patients. More research is needed to better understand the role of these autoantibodies fore FMS pain sensitivity and pain.

09/09/2025

Autoantibodies are generated by patients to attack their body’s own tissues. A group of researchers recently tried to assess their role in fibromyalgia (FMS). They tested blood from 184 patients with FMS, 25 healthy controls, and 30 disease controls with primarily neuropathies and myositis. They found that 68 of the FMS patients had autoantibodies, but none of the healthy participants or disease controls. These antibodies were bound to neurons that sense and transmit pain and glial cells that provide support for the nerves. Certain subgroups of the antibody patterns were associated with symptoms (like burning pain, stabbing pain and tingling). The presence of autoantibodies also correlated with lower pain scores. A better understanding of the subgroups of patients and the role of the immune system may lead to better and more personalized treatments in patients with FMS.

Address

1600 SW Archer Road, Rm G-056
Gainesville, FL
32610

Opening Hours

Monday	8am - 5pm
Tuesday	8am - 5pm
Wednesday	8am - 5pm
Thursday	8am - 5pm
Friday	8am - 5pm

Telephone

(352) 265-8901

Website

http://rheum.med.ufl.edu/

Alerts

Be the first to know and let us send you an email when UF Center for Musculoskeletal Pain Research posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to UF Center for Musculoskeletal Pain Research:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Want your practice to be the top-listed Clinic in Gainesville?